Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Greenlights COVID Boosters for ‘High-Risk’ Groups but Warns that Blanket Campaigns Could Harm Global Pandemic Response 22/12/2021 Elaine Ruth Fletcher WHO has issued new advice to countries supporting booster campaigns for “high risk groups” but still opposing “blanket” campaigns – or vaccines for children and adolescents under the age of 18. The latter, top WHO officials contend, could divert too many vaccines from low-and-middle member states that have low vaccination coverage rates – leading to […] Continue reading -> Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Driven by Omicron, Africa Faces Steep Wave of New COVID Infections; WHO in UN-Geneva Briefing that Excludes Most African Media 21/12/2021 Elaine Ruth Fletcher Driven by Omicron, Africa is facing a steep wave of new COVID infections – last week reporting the fourth highest number of cases ever recorded in a single week, said WHO Director General Dr Tedros Adhanom Ghebreyesus on Monday. He was speaking at an exclusive media briefing in Geneva behind closed doors to a handful […] Continue reading -> Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Moderna Says Existing COVID Vaccine Booster Appears Effective Against Omicron – Higher Dose Performs Even Better 20/12/2021 Elaine Ruth Fletcher In what should be reassuring news for health systems the world over, preliminary lab results suggest that Moderna’s authorised COVID booster dose of 50 µg offers 37-fold more protection against Omicron than the first two vaccine jabs after 29 days. And a 100 µg booster -comparable to the dose received in the first two shots […] Continue reading -> WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Approves Novavax Covid Vaccine for Emergency Use, to Aid Supply In Lower-Income Countries 17/12/2021 Aishwarya Tendolkar The World Health Organization on Friday issued an emergency use listing for a novel COVID vaccine produced – in a move that should help ramp up new rounds of COVID vaccine distributions to low- and middle-income countries in coming months. Approval of the novel vaccine, developed by the US-based firm Novavax, and to be produced […] Continue reading -> Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Still A Long Way To Go Until Everyone Is Safe From COVID – and Vaccine Numbers Don’t Tell The Whole Story 17/12/2021 Riccardo Lampariello As more vaccine supplies finally become available to the world’s low-and middle-income countries (LMICs), the latent challenges that should have been addressed long before have emerged. Those include vaccine hesitancy and the ability of weak health systems to mount mass vaccination campaigns amidst other pressing health needs. Global policymakers need to shift their attention from […] Continue reading -> Posts navigation Older postsNewer posts